Pharmaceutical Commerce

NOVEMBER 21, 2023

Delivering COVID-19 vaccines to 7.8 This white paper dives into vaccine distribution plans and what vaccine manufacturers, distributors and administrators can take away from this monumental time in both the industry and history. billion people was a daunting challenge that stretched supply chains past their limits.

Vaccines 40

Vaccines 40

BioPharm

APRIL 23, 2023

Delivering COVID-19 vaccines to 7.8 This white paper dives into vaccine distribution plans and what vaccine manufacturers, distributors and administrators can take away from this monumental time in both the industry and history. billion people was a daunting challenge that stretched supply chains past their limits.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

DECEMBER 5, 2022

With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.

Vaccines 98

Vaccines Communication Immunization 98

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccines 59

Vaccines Communication 59

Pharmaceutical Technology

MARCH 23, 2023

China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 64

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Vaccines 98

Vaccines Communication FDA 98

pharmaphorum

MARCH 25, 2021

As vaccines for the coronavirus help us begin to chart a course away from the emergency phase of the pandemic, many within healthcare are now starting to take stock of the health tech experience of the last 12 months and plan for further digital transformation of the NHS. The NHS’ digital future.

Vaccines 144

Vaccines 144

Pharma Marketing Network

DECEMBER 31, 2024

For instance, reminders about flu vaccines during peak season can boost patient engagement. High-quality blog posts, white papers, and case studies can boost your visibility. Use Personalized Communication One-size-fits-all is no longer effective.

HIPAA 52

HIPAA Communication Patient Care Vaccines 52

BioPharm

OCTOBER 8, 2023

The significant growth of the biologic drug market, bolstered by the COVID-19 pandemic and the development of relevant vaccines, along with the growing complexity and fragility of biologic drugs, has led to a need for improved freezing and thawing methods. Check out this white paper to learn more.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

SEPTEMBER 16, 2022

And despite the recent pandemic that forced the industry to develop and deliver treatments and vaccines all over the world, the issue of reducing emissions has remained high on industry leaders’ agendas. Download the white paper to learn more. [1] Industry awareness of the issues. Linda Schwär, VP Marketing, Berlinger & Co.

Vaccines 52

Vaccines Labelling 52

ISPE

MARCH 1, 2023

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. Previous Slide ◀︎ Next Slide ▶︎ Download White Paper To download this white paper, complete the form below.

Communication 52

Communication Vaccines 52

ISPE

FEBRUARY 1, 2023

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. Previous Slide ◀︎ Next Slide ▶︎ Download White Paper To download this white paper, complete the form below.

Communication 52

Communication Vaccines 52

Pharmaceutical Technology

MARCH 27, 2023

National Resilience will use the funding to establish a significant domestic biomanufacturing capacity and capabilities for vaccines, nucleic acids including mRNA, and biologics including antibodies, proteins and multi-specifics. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 52

Vaccines Communication 52

ISPE

JANUARY 3, 2023

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. Download White Paper. To download this white paper, complete the form below. Company Name. Company Type. Company Type.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Vaccines 52

Pharmaceutical Technology

DECEMBER 1, 2022

Its development pipeline comprises chimeric antigen receptor (CAR)-T cell therapies, CD47 immune checkpoint inhibitor and Guanylyl Cyclase C (GCC) cancer vaccine. The GCC Vaccine is being analysed in Phase II clinical trials.

Immunization 52

Immunization Vaccines Communication 52

Pharmaceutical Technology

OCTOBER 28, 2022

For more information on this, please download our white paper. For example, the Covid-19 pandemic brought messenger ribonucleic acid (mRNA) vaccines into international prominence. Because mRNA is highly unstable, these vaccines have had to be stored and/or transported at -80°C to avoid degradation.

Vaccines 52

Vaccines Documentation FDA 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Pharmaceutical Companies Pharmaceutical Companies Vaccines 59

pharmaphorum

FEBRUARY 24, 2022

BIVDA really hope that the white paper will help inform UK policy makers and give them areas to focus on which we, as a coalition, see as critical to start moving this issue forward.”.

Documentation 52

Documentation Vaccines 52

ISPE

NOVEMBER 3, 2022

A white paper on regulatory development for low- to middle-income countries, international collaboration on methods for producing gene therapies, and public/private partnerships to support therapies for extremely rare disorders are other steps to consider.

Communication 98

Communication FDA Documentation Vaccines 98

ISPE

SEPTEMBER 11, 2023

Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” www.fiercepharma.com/manufacturing/sanofi-pumps-554m-into-new-vaccine-manufacturing-facility-eastern-france 41 Boccard. New Project: Evolutive Vaccines Facility for Sanofi.” www.boccard.com/evolutive-vaccines-facility-for-sanofi/ 42 Amgen.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

ISPE

AUGUST 29, 2022

Accumulus Synergy White Paper. The rapid transition between clinical studies to emergency use authorization, and then to the world’s first fully approved vaccine in under two years, highlights the potential of biopharmaceutical companies and health authorities. Journal of Pharmaceutical Sciences (2021). doi:10.1016/j.xphs.2021.09.046.

Documentation 52

Documentation FDA Communication Packaging 52

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunization Communication 64

Pharmaceutical Technology

MARCH 20, 2023

The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Poolberg Pharma is deploying AI algorithms on early-stage clinical data to prioritise and reposition vaccine candidates for respiratory syncytial virus.

Vaccines 90

Vaccines Communication Hospitals 90

Pharmaceutical Technology

DECEMBER 13, 2022

To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. Before the COVID-19 pandemic, 25-50% of vaccines were wasted due to cold chain issues.

Vaccines 52

Vaccines Communication Documentation 52

Pharmaceutical Technology

MARCH 22, 2023

Among other things, supply chain optimisation, maintaining access to affordable vaccines, and supporting innovation for unmet clinical needs will be the discussion topics, she adds. “The European Commission plans to launch its revised EU pharmaceutical package in Q1 2023 to ease drug shortages,” she says.

Packaging 105

Packaging FDA Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

DECEMBER 15, 2022

The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. The organizations plan to use data analytics to improve manufacturing processes. Additionally, Merck & Co.

Vaccines 105

Vaccines Packaging Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

MARCH 1, 2023

Oragenics and Inspirevax have signed a license agreement to develop the former’s lead intranasal vaccine candidate for Covid-19, NT-CoV2-1. As part of the exclusive international agreement, Oragenics agreed to pursue the vaccine development with the new BDX301 intranasal mucosal adjuvant of Inspirevax.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

MARCH 21, 2023

Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease.

Packaging 59

Packaging FDA Vaccines Communication 59

Pharmaceutical Technology

MAY 9, 2023

For Jamaels, whose track record in managing complex operations and delivering process improvements spans GSK Vaccines and one of the world’s largest companies, GE, the technological shift is an exciting development: “I’m passionate about the digital transformation that our industry is going through,” he says.

Vaccines 52

Vaccines Process Improvement Communication 52

Pharmaceutical Technology

DECEMBER 8, 2022

Prefilled syringes are increasingly being recognised as the safest method of packaging injectable drugs, and they offer a number of advantages when administering vaccines specifically. Lessons from the Pandemic: Building a Better Prefilled Syringe. By Datwyler. United Kingdom. United States.

Packaging 98

Packaging Vaccines Communication 98

Pharmaceutical Technology

MARCH 22, 2023

During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 20, 2023

During the pandemic, Teddy Lab Wuxi have supported over dozens of COVID drug or vaccine clinical trials, many of which are working closely with Cerba Research, and as a result, multiple candidates have been approved under emergency use in different countries. Teddy Lab also reached multiple milestones in the past 5 years.

Research Laboratories 52

Research Laboratories Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 5, 2023

The swift development of COVID-19 vaccines was an unprecedented scientific and collaborative achievement by government, regulators, research institutions, and the pharmaceutical industry.

Vaccines 69

Vaccines Communication Labelling 69

Pharmaceutical Technology

FEBRUARY 20, 2023

The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020. A lot of unique assays have already been added to a common portfolio and colleagues from both businesses are working well together.

Vaccines 52

Vaccines Communication Immunization 52

Pharmaceutical Technology

JANUARY 25, 2023

The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Controlant’s real-time visibility platform and command center is already transforming vaccine distribution by meticulously tracking shipments from origin sites to vaccination hubs.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 59

Pharmaceutical Technology

FEBRUARY 15, 2023

To ensure temperature-critical medicines such as vaccines are fit for purpose, cold chains must be carefully monitored, and products tracked throughout the entire journey from manufacturer to patient. Cold chain shipments are particularly vulnerable.

Vaccines 52

Vaccines Communication 52